A small team of Boston entrepreneurs are developing Curoverse, an infrastructure that helps store and analyze human genetic data for biomedical research. The company raised its first $1.5 million in a seed round today, according to VentureBeat.
Hatteras Venture Partners, Common Angels, Boston Global Ventures, Point Judith Ventures, and MassVentures, among others, participated in the said round, the report said.
The technology of Curoverse is still in private data, but its founders are planning a 2014 release for its initial set of commercial products, the report stated.
According to Curoverse chief executive Adam Berrey, researchers are expected to use the platform to initially make data-driven discoveries in neonatal screening, rare inherited diseases, and oncology. Curoverse does not perform the analysis, but it can store very large amounts of data distributes across data centers, the report explained.
The company is building its products on top of Arvados, which is a free and open source platform that Harvard uses for genomic analysis. Curoverse is presently developing an enterprise-ready and secure version of Arvados, VentureBeat reported.
Join the Conversation